Most Recent
The applicant in a class action against NAB superannuation trustee NULIS has lost his bid to have a judge determine aggregate damages at an initial trial.
Drug company Ono Pharmaceutical has faced tough questioning by an appeals court in a fight with IP Australia over a decision that secured it a patent extension for its cancer immunotherapy drug Opdivo.
A judge has left open the possibility that aggregate damages could be awarded in a class action against US auto giant Ford on behalf of 185,000 vehicle owners over their defective cars.
Boral has denied that shareholders bringing two class actions against it over financial irregularities in its North America windows business suffered any loss, saying that its systems helped spot and prevent the financial manipulation from continuing.
Merck Sharp & Dohme is seeking to overturn a judgment refusing an extension of a patent covering its Januvia and Janumet diabetes drugs that would have seen the US drug maker of retaining a monopoly over the multibillion dollar medicines beyond July 2022.
The applicant in a Federal Court class action against NAB superannuation trustee NULIS has been ordered to find a sample group member in light of a landmark Victoria Supreme Court ruling that found the plaintiff in a similar class action could not establish any loss.
The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an "untenable" patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.
IP Australia has appealed a ruling granting drug company Ono Pharmaceutical a patent extension for a cancer immunotherapy drug, calling it an "impermissible gloss" on the Patents Act that is at odds with the law's purpose.
In a win for a long-running class action against US auto giant Ford on behalf of owners of 70,000 vehicles, a judge has found that cars installed with PowerShift transmissions were defective.
A judge has overturned a ruling from the Australian Patent Office that shortened the amount of time available to companies under patent term extensions, saying a "liberal rather than literal" reading was needed to achieve the extension regime's goals of compensating holders of drug patents for the lengthy time required to obtain regulatory approval to market their drugs.